Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
Top Stock Reports for NVIDIA, UPS & Intuit
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), United Parcel Service, Inc. (UPS), and Intuit Inc. (INTU).
Biogen (BIIB) Q4 Earnings Top, Stock Down on Weak 2022 View
by Zacks Equity Research
Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The stock declines on weak sales and earnings guidance for 2022.
Novo Nordisk's (NVO) Q4 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Gilead (GILD) Q4 Earnings Miss on Legal Settlement Charges
by Zacks Equity Research
Gilead (GILD) misses on earnings but beats on sales in the fourth quarter. While the HIV business maintains momentum on Biktarvy, sales of Veklury decline.
Zacks.com featured highlights include: Danaos Corp., Earthstone Energy Inc., Hanmi Financial Corp., Archer-Daniels-Midland Co. and Vertex Pharmaceuticals Inc
by Zacks Equity Research
Danaos Corp., Earthstone Energy Inc., Hanmi Financial Corp., Archer-Daniels-Midland Co. and Vertex Pharmaceuticals Inc are highlighted in this Screen of the Week article.
Zacks Industry Outlook Highlights: Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen
by Zacks Equity Research
Regeneron, Vertex Pharmaceuticals, Dynavax Technologies Corp. and Repligen are highlighted in this Industry Outlook article.
4 Top Biotech Stocks to Gain Amid Industry Challenges
by Ekta Bagri
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position VRTX, REGN, DVAX and RGEN well amid the volatility.
5 Stocks With Recent Price Strength Amid Wall Street Turmoil
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are DAC, ESTE, HAFC, ADM and VRTX.
Top Stock Picks for Week of January 31, 2022
by Panel Of Zacks Experts
A Biomed Stock Well Positioned for Outperformance and a Building Materials Company Befitting From a Robust Demand Environment.
Dr. Reddy's (RDY) Q3 Earnings, Sales Increase Year Over Year
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.
Regeneron (REGN) Withdraws sBLA for Libtayo in Cervical Cancer
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi voluntarily withdraw the supplemental biologics license application for Libtayo in second-line treatment of advanced cervical cancer.
Looking for a Growth Stock? 3 Reasons Why Vertex (VRTX) is a Solid Choice
by Zacks Equity Research
Vertex (VRTX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More
by Zacks Equity Research
Earnings updates from Vertex (VRTX) and pipeline updates are among a few key highlights from the biotech sector during the past week.
Vertex (VRTX) Q4 Earnings & Sales Beat, '22 View Upbeat
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) earnings and sales surpass estimates for the fourth quarter of 2021. The company provides its revenue guidance for 2022.
Vertex Pharmaceuticals (VRTX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 2.74% and 4.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals Inc., Marten Transport, Nucor, Seagate Technology and Sanderson Farms
by Zacks Equity Research
Vertex Pharmaceuticals Inc., Marten Transport, Nucor, Seagate Technology and Sanderson Farms are included in this blog.
5 Buy-Ranked Stocks Likely to Beat on Earnings This Week
by Sejuti Banerjea
The Zacks Rank and ESP are still a solid combination to predict earnings beats.
The Zacks Analyst Blog Highlights: Tesla Inc., Steel Dynamics Inc., United Rentals Inc., Freeport-McMoRan Inc. and Vertex Pharmaceuticals Inc.
by Zacks Equity Research
Tesla Inc., Steel Dynamics Inc., United Rentals Inc., Freeport-McMoRan Inc. and Vertex Pharmaceuticals Inc. are included in this blog.
Should You Buy Vertex Pharmaceuticals (VRTX) Ahead of Earnings?
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are likely to focus on Vertex Pharmaceuticals' (VRTX) CF product revenues, especially sales of its triple combo CF drug Trikafta/Kaftrio, and non-CF pipeline progress.
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis
by Zacks Equity Research
AbbVie (ABBV) secures approval in the United States for Skyrizi to treat adult patients with active psoriatic arthritis.
Will Lower Aggregate Revenues Hurt Intel's (INTC) Q4 Earnings?
by Zacks Equity Research
Intel's (INTC) performance in fourth-quarter 2021 is likely to reflect headwinds in the enterprise business of the data center segment.
Silicon Motion (SIMO) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Silicon Motion's (SIMO) performance in the fourth quarter of 2021 is likely to have benefited from increased sales of SSD and eMMC and UFS controllers.
PTC Gearing Up for Q1 Earnings: What is in the Offing?
by Zacks Equity Research
PTC is likely to have reported higher year-over-year revenues in first-quarter fiscal 2022, driven by significant growth across all product segments and regions.
Vertex Pharmaceuticals (VRTX) Stock Moves -0.23%: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $228.08, marking a -0.23% move from the previous day.